Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 4/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903628 | 0.85 | SMN1; SMN2 (0.36) | KDM4EALDH1A1CYP1A2SMN1; SMN2MAPK10 | |
| SCHEMBL2628933 | 0.76 | — | — | |
| SCHEMBL21358923 | 0.75 | OGA (0.43) | KDM4EALDH1A1CYP1A2SMN1; SMN2NPC1 | |
| SCHEMBL3129610 | 0.75 | KDM4E (0.42) | KDM4EALDH1A1CYP1A2SMN1; SMN2NPC1 | |
| SCHEMBL20284239 | 0.75 | ALDH1A1 (0.50) | KDM4EALDH1A1CYP1A2SMN1; SMN2NPC1 | |
| SCHEMBL3129621 | 0.74 | OGA (0.45) | KDM4EALDH1A1CYP1A2SMN1; SMN2NPC1 | |
| SCHEMBL21369613 | 0.74 | OGA (0.42) | KDM4EALDH1A1CYP1A2SMN1; SMN2NPC1 | |
| SCHEMBL4360107 | 0.73 | CCNE1 (0.37) | KDM4EALDH1A1SMN1; SMN2MAPK10NPC1 | |
| SCHEMBL1808824 | 0.71 | — | — | |
| SCHEMBL6180872 | 0.71 | HTT (0.40) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828184-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR | Medshine Discovery Inc. (CN) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020038394-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR | 南京明德新药研发有限公司 | 2020-02-27 | — | — | WO | disclosed |
| CN-1863800-B | Novel compounds that modulate PPAR type receptors, and use thereof in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV | 2013-07-24 | — | — | CN | disclosed |
| US-8022079-B2 | Methods of modulating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-09-20 | — | — | US | disclosed |
| EP-1638964-B1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-7968560-B2 | Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-22 | — | — | US | disclosed |
| US-7625914-B2 | Compounds that modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| CN-1863800-A | Novel compounds that modulate PPAR type receptors, and use thereof in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV (FR) | 2006-11-15 | — | — | CN | disclosed |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-07-06 | — | — | US | disclosed |
| EP-1638964-A1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113331-A1 | NOVEL COMPOUNDS THAT MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | PPARG, PPARA, PPARD | KDM4E 3480/4885ALDH1A1 484/4885CYP1A2 588/4885 |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | KDM4E 3404/4885ALDH1A1 579/4885CYP1A2 382/4885 |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | PPARG, PPARD, PPARA | KDM4E 3267/4885ALDH1A1 578/4885CYP1A2 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.